PTU-130 Indeterminate faecal calprotectin identifies significant small bowel crohn’s disease

IntroductionNICE and BSG have recommended the use of faecal calprotectin (FCP) in investigating patients with suspected small bowel Crohn’s disease (SBCD). There is currently inadequate data to advise on management for intermediate ranges of FCP of 50 ug/g to 250 ug/g. This study aims to assess whether this intermediate FCP level is clinically significant for diagnosing active SBCD.MethodWe analysed patients with suspected SBCD at Hereford County Hospital from 2013–2016 who underwent SB imaging and FCP testing. Patient’s notes, laboratory results and clinical imaging were reviewed and Fisher’s exact test was used for statistical analysis.Results48 patients underwent FCP with small bowel cross-sectional imaging. For those with an elevated FCP >250 ug/g, there was a positive predictive value of 75% for diagnosing SBCD and a negative predictive value of 70% for those with an FCP 250217Intermediate range 50–25073Negative FCP250 ug/g and should therefore be considered as a significant finding.Disclosure of InterestNone Declared